Introduction & background
Company Presentation
Ongoing Projects
Marketed Products
CRO Services
About us
Products & Services
R&D Structure
Commercial Targets
  Contact us
About us: News
Go back
Rivastigmine Patch for LATAM markets

Amarin Technologies S.A. has licensed its Rivastigmine Patch to Asofarma S.A., for Brazil and Argentina markets.

Registration is expected to be accomplished during 2013.

Rivastigmine patch is a drug-in-adhesive transdermal system which inhibits the cholinesterase activity and is indicated for the treatment of Alzheimer disease and Parkinson's disease dementia.

Introduction & background | Key Personnel
Site Map | Legal Statement

Amarin Technologies S.A. © 2018   Design & Development: Mandarina